| New from NCI |
| How Breast Cancer Risk Assessment Tools Work |
 |
|
NCI researchers discuss how breast cancer risk assessment tools are created and how people can use them to understand and manage risk.
Read More
|
| Program Improves Physical Activity in Cancer Survivors |
 |
|
A program in Texas helped minority and medically underserved cancer survivors get much more physical activity, according to a new study. People who took part in the study also reported improved physical functioning and quality of life.
Read More
|
Video: Improving Taste and Smell During Cancer Treatment
Cancer treatment can cause changes in taste or smell. Although you can’t prevent these problems, the tips in this video can help you deal with them.
Watch the Video
|
Targeted Therapy Slows Growth of ALK-Positive Lung Cancers
Lorlatinib (Lorbrena) is better than crizotinib (Xalkori) as a first treatment for people with ALK-positive advanced non-small cell lung cancer, according to new clinical trial results. Treatment with lorlatinib also seemed to help prevent these cancers from spreading to the brain.
Read More
|
| FLOT Improves Survival for Some with Esophageal Cancer |
 |
|
For people with locally advanced esophageal cancer, a chemotherapy regimen called FLOT is the preferred treatment, according to results from a large clinical trial. People treated with FLOT lived much longer than those treated with another regimen.
Read More
|
New Immunotherapy Approach Shows Promise in Solid Tumors
Early findings from a small clinical trial show that a new cellular immunotherapy approach using genetically engineered white blood cells may be effective in treating metastatic solid tumors.
Read More
|
Targeted Therapy Approved for Myelodysplastic Syndrome
The Food and Drug Administration has approved the targeted therapy imetelstat (Rytelo) to treat certain types of myelodysplastic syndrome. It is used in adults with anemia who need blood transfusions and have not responded to other treatments.
Read More
|
